Products for Research Use Only
RegisterLogin

Zomiradomide

CAT: 0804-HY-153368-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-153368-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Zomiradomide is an orally active PROTAC degrader for IRAK4 (DC50=6 nM), thereby inhibiting the NF-κB signaling pathway. Zomiradomide acts also as a molecular glue, recruiting Ikaros and Aiolos, and mediating their degradation (DC50 for Ikaros is 1 nM), thereby activating the type I IFN signaling pathway[1][2][3]. (Pink: target protein ligand PROTAC IRAK4 ligand-5 , Blue: E3 ligase ligand Thalidomide-4-Br (HY-W039116), Black: linker (HY-168313) )
CAS Number
2655656-99-6
Product Name Alternative
KT-413
UNSPSC
12352005
Target
IFNAR; IRAK; NF-κB; PROTACs
Type
Reference compound
Related Pathways
Immunology/Inflammation; NF-κB; PROTAC
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/kt-413.html
Purity
95.43
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(N1C2C(NC(CC2)=O)=O)C3=CC=CC(NCCC(C4)CC4(C5)CN5C[C@H]6CC[C@H](C(SC7=C8)=NC7=CC(C(C)(O)C)=C8NC(C9=CC=CC(C(F)(F)F)=N9)=O)CC6)=C3C1=O
Molecular Formula
C45H48F3N7O6S
Molecular Weight
871.97
References & Citations
[1]Weiss Matthew M. Preparation of benzothiazole derivatives as IRAK degraders and uses thereof. World Intellectual Property Organization, WO2021127190 A1. 2021-06-24.|[2]Zeng S, et al. Current advances and development strategies of orally bioavailable PROTACs. Eur J Med Chem. 2023 Dec 5;261:115793.|[3]Weiss MM, et al., Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell Lymphoma. J Med Chem. 2024 Jul 11;67 (13) :10548-10566.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1

Alternative Products

CatalogName
GTR19220585-01Zomiradomide

Popular Products